Format
Sort by
Items per page

Send to

Choose Destination

Best matches for TETRABENAZINE/TU:

Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. Frank S et al. JAMA Neurol. (2017)

Treatment options for chorea. Bashir H et al. Expert Rev Neurother. (2018)

Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Caroff SN et al. J Comp Eff Res. (2018)

Search results

Items: 1 to 20 of 313

1.

Tardive Dyskinesia: New Treatments Available.

Limandri BJ.

J Psychosoc Nurs Ment Health Serv. 2019 May 1;57(5):11-14. doi: 10.3928/02793695-20190410-02.

PMID:
31042295
2.

Real-World Experience With VMAT2 Inhibitors.

Niemann N, Jankovic J.

Clin Neuropharmacol. 2019 Mar/Apr;42(2):37-41. doi: 10.1097/WNF.0000000000000326.

PMID:
30870235
3.

The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.

McIntyre RS, Calabrese JR, Nierenberg AA, Farahmand K, Yonan C, Siegert S, Burke J.

J Affect Disord. 2019 Mar 1;246:217-223. doi: 10.1016/j.jad.2018.12.023. Epub 2018 Dec 17.

4.

Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Estevez-Fraga C, Zeun P, López-Sendón Moreno JL.

Drugs Aging. 2018 Nov;35(11):959-971. doi: 10.1007/s40266-018-0590-y. Review.

PMID:
30357723
5.

Deutetrabenazine for the treatment of Huntington's chorea.

Bashir H, Jankovic J.

Expert Rev Neurother. 2018 Aug;18(8):625-631. doi: 10.1080/14737175.2018.1500178. Epub 2018 Jul 17. Review.

PMID:
29996061
6.

Evaluating depression and suicidality in tetrabenazine users with Huntington disease.

Schultz JL, Killoran A, Nopoulos PC, Chabal CC, Moser DJ, Kamholz JA.

Neurology. 2018 Jul 17;91(3):e202-e207. doi: 10.1212/WNL.0000000000005817. Epub 2018 Jun 20.

PMID:
29925548
7.

Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia.

Atlas SJ, Agboola F, Curfman G.

JAMA Intern Med. 2018 Aug 1;178(8):1110-1112. doi: 10.1001/jamainternmed.2018.2463. Review. No abstract available.

PMID:
29913006
8.

Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.

[No authors listed]

Med Lett Drugs Ther. 2018 Apr 23;60(1545):65-68. No abstract available.

PMID:
29667946
9.

VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.

Kim AP, Baker DE, Levien TL.

Consult Pharm. 2018 Apr 1;33(4):201-209. doi: 10.4140/TCP.n.2018.201. Review.

PMID:
29609698
10.

2018 New Drug Update.

Hussar DA, Finn LA.

Consult Pharm. 2018 Apr 1;33(4):188-198. doi: 10.4140/TCP.n.2018.188.

PMID:
29609697
11.

Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H.

Cochrane Database Syst Rev. 2018 Mar 19;3:CD000208. doi: 10.1002/14651858.CD000208.pub2. Review.

12.

Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening.

Xiao H, Sun M, Zhao R, Hong H, Zhang A, Zhang S, Liu F, Zhang Y, Liu Y, Zhu L, Kung HF, Qiao J.

J Pharm Biomed Anal. 2018 May 30;154:48-56. doi: 10.1016/j.jpba.2018.02.063. Epub 2018 Mar 3.

PMID:
29533858
13.

Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.

Dean M, Sung VW.

Drug Des Devel Ther. 2018 Feb 15;12:313-319. doi: 10.2147/DDDT.S138828. eCollection 2018. Review.

14.

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Niemann N, Jankovic J.

Drugs. 2018 Apr;78(5):525-541. doi: 10.1007/s40265-018-0874-x. Review. Erratum in: Drugs. 2018 Mar 10;:. Dosage error in article text.

PMID:
29484607
15.

Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States.

Sung VW, Iyer RG, Gandhi SK, Shah-Manek B, DiBonaventura M, Abler V, Claassen DO.

Curr Med Res Opin. 2018 Apr;34(4):643-648. doi: 10.1080/03007995.2018.1435518. Epub 2018 Feb 16.

PMID:
29383957
16.

Two New Drugs for Tardive Dyskinesia Hit the Market.

Morrow T.

Manag Care. 2018 Jan;27(1):35-36.

17.

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

El-Sayeh HG, Rathbone J, Soares-Weiser K, Bergman H.

Cochrane Database Syst Rev. 2018 Jan 18;1:CD000458. doi: 10.1002/14651858.CD000458.pub3. Review.

18.

Deuterium Tetrabenazine for Tardive Dyskinesia.

Cummings MA, Proctor GJ, Stahl SM.

Clin Schizophr Relat Psychoses. 2018 Jan;11(4):214-220. doi: 10.3371/CSRP.CUPR.010318. Review.

PMID:
29341821
19.

Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.

Sarva H, Henchcliffe C.

Expert Rev Clin Pharmacol. 2018 Mar;11(3):209-217. doi: 10.1080/17512433.2018.1429264. Epub 2018 Jan 23. Review.

PMID:
29338466
20.

Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions.

Contreras-Mora H, Rowland MA, Yohn SE, Correa M, Salamone JD.

Pharmacol Biochem Behav. 2018 Mar;166:13-20. doi: 10.1016/j.pbb.2018.01.001. Epub 2018 Jan 6.

PMID:
29309800

Supplemental Content

Loading ...
Support Center